Targeting Copper Metabolism to Improve Cancer Therapy Efficacy
Background
Acute Lymphoblastic Leukemia (ALL), one of the most common childhood cancers, is a type of cancer that originates in the bone marrow and can spread to various parts of the body, including the central nervous system (CNS) through cerebrospinal fluid. This can lead to deadly complications requiring intensive treatments. These treatments, however, often come with significant drawbacks, such as neurotoxicity and eventual patient relapse with CNS involvement. While the aggressive spread of ALL to the CNS poses significant treatment challenges, the unique metabolic adaptations that allow cancer cells to thrive in the nutrient-sparse cerebrospinal fluid may also open avenues for novel therapeutic strategies targeting these biological vulnerabilities.
Technology Overview
Boston Children’s Hospital researchers identified copper metabolism as a targetable nutritional dependency in ALL. Using an in vivo CRISPR screen in mouse xenograft models, the inventors discovered that ALL cells rely on copper availability to maintain mitochondrial complex IV activity and sustain nucleotide synthesis. Copper depletion, achieved either genetically or through a combined dietary/pharmacological intervention, significantly inhibits leukemia proliferation both systemically and within the CNS. Mechanistic studies show that copper loss disrupts electron transport chain (ETC ) function, suppresses nucleotide production, and thereby halts leukemic cell growth. Importantly, dietary copper depletion synergizes with standard-of care methotrexate, enhancing therapeutic efficacy while potentially reducing neurotoxic dosing requirements. This technology establishes copper depletion as a novel, actionable strategy to impair leukemia metabolism, especially in the nutrient-poor CSF environment where alternative treatments are limited.
Applications
- Acute lymphoblastic leukemia
Advantages
- Targets and disrupts oxidative phosphorylation in leukemia cells through copper depletion.
- Slows leukemia cell proliferation, also in the CNS, where treatment options are more challenging.
- Enhances the effectiveness of existing treatment regimens, potentially reducing treatment-associated neurotoxicity and improving patient outcomes.
- Provides a novel therapeutic approach by identifying and exploiting a specific micronutrient dependency in ALL.
